Sorafenib-related hand-foot skin reaction improves, not worsens, with continued treatment

Clinical Cancer Research

Volumn 15, Issue 24, 2009, Pages 7749-

  Flaherty, Keith T ^a   Brose, Marcia S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; SORAFENIB;

DISEASE SEVERITY; HAND FOOT SYNDROME; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LETTER; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; THYROID CARCINOMA;

EID: 73349100990     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1190     Document Type: Letter

References (4)

1. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15:1411-6.
2. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
4. Sosman JA, Flaherty KT, Atkins MB, et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008;26, (May 20 suppl; abstr 5011).